The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine

National Taiwan University Clinical Trial Center

Status: Not yet enrolling

Conditions: Cabotegravir; AIDS; Quality of Life; Rilpivirine; Viral Control

Treatments: Other: Observational study, non-interventional

Study type: Observational

Funder types: Other

Identifiers

NCT07131826

202503037RINA

Details and patient eligibility

About

"AIDS" was once regarded as the Black Death of the 20th century. However, with the advent of cocktail therapy, the survival rate of infected people has been greatly improved and the average life expectancy has been increased. Today, AIDS is considered a chronic disease, just like hypertension and diabetes. As long as you have regular checkups and take medication on time every day, you can complete the treatment, just like a normal person. However, there is still a risk of missing medication when taking it every day, and long-term missed medications can easily lead to drug resistance and increase the risk of treatment failure. After the HIV-infected person has stabilized the viral load, their mobility, self-care and daily activities are no different from those of normal people. However, they experience side effects such as fatigue, lack of energy, difficulty sleeping, depression, changes in appearance, tension and anxiety, dizziness, headache, vomiting, etc., which affect their quality of life. The long-acting AIDS injection is a long-acting dosage form for intramuscular injection. It has been included in the national health insurance reimbursement standards. Treatment with long-acting injections can reduce the risk of infected people forgetting to take medicine, and there is no need to worry about the exposure of the disease when storing the medicine. Through this study, we hope to collect the results of long-acting injections for stable HIV treatment cases (health status, daily activities, injection site, satisfaction), and confirm that long-acting injections can significantly improve the quality of daily life of HIV-infected people.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

18 years and above Clinical diagnosis of HIV infection completed long-acting injectable treatment Accept the questionnaire

Exclusion criteria

Not clinical diagnosis of HIV infection Do not accept questionnaires

Trial design

200 participants in 1 patient group

AIDS patients after long-acting injection of cabotegravir and rilpivirine

Description:

AIDS patients after long-acting injection of cabotegravir and rilpivirine

Treatment:

Other: Observational study, non-interventional